Evaluation of Anti-Histaminic and Bronchodilator Activity of Linga Mathirai (Formal Siddha Drug)c
‘Asthma’ is a Greek word which means ‘breathless’ or ‘to breathe with open mouth’. Bronchial asthma is an important allergic disorder. Prevalence of asthma is between 100 and 150 million people around the globe and India has an estimated 15-20 million asthmatics. The cost of medication in India was estimated as US$ 30 per month. Aim of the study is to investigate the safety and efficacy of Linga Mathirai (LM) (Siddha Drug) for the treatment of Bronchial asthma. Antihistaminic activity was studied in guinea pigs using histamine-induced bronchospasm where preconvulsive dyspnea was used as an end point following exposure to histamine aerosol. It was evaluated for antihistamine and bronchodilator activities and it administrated at the doses of 100, 200 and 400 mg/kg body weight. A dose response curve for histamine + LM is lower, when compared with histamine induced contraction (p<0.05) at moderate dose level. The LM at moderate dose level significantly prolonged the latent period of convulsions as compared to control following the exposure of histamine aerosol. The result of present study shows that Linga Mathirai significantly protected the Guinea pigs against histamine-induced bronchospasm. Significant increase in-between pre and post treatment time (**P<0.01). The present study reveals that the Linga Mathirai (LM) can be more effective in the treatment of Bronchial asthma.